{"id":"W4387825536","doi":"10.1016/j.annonc.2023.09.2347","title":"1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Chugai Pharmaceutical; Aptitude Health; Genentech; F. Hoffmann-La Roche; Grifols; Eisai; Ipsen; Sociedad Española de Oncología Médica; BeiGene; Mirati Therapeutics; Regeneron Pharmaceuticals; Boston Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Exelixis; Sanofi; Amgen; Pfizer; Takeda Pharmaceuticals International; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Discontinuation; Gastroenterology; Adverse effect; Oncology; Pharmacokinetics; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004415415,0.0003311059,0.0006662733,0.0001833474,0.0002055865,0.0003423003,0.0002170834,0.0004156152,0.001220444],"category_scores_gemma":[0.000667158,0.0001490298,0.0005709594,0.0001825679,0.0002828683,0.0003070889,0.0001463633,0.001049161,0.0004145413],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004973232,"about_ca_system_score_gemma":0.0004691337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001298954,"about_ca_topic_score_gemma":0.002124046,"domain_scores_codex":[0.9998387,0.00006534153,0.000009239082,0.00002129802,0.000024222,0.0000411203],"domain_scores_gemma":[0.9997942,0.00006117927,0.00003469771,0.00001982779,0.00001583422,0.00007423308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5200521,0.00899948,0.07456259,0.0003422404,0.001159453,0.001006772,0.0002186855,0.003860111,0.1584334,0.0004081684,0.003388283,0.2275687],"study_design_scores_gemma":[0.04709015,0.4618779,0.4204279,0.00006169396,0.001642408,0.002541499,0.0001163184,0.007295306,0.04668012,0.0003650935,0.01182436,0.00007716858],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951494,0.001858624,0.0001579662,0.0001780427,0.00004306357,0.00005126929,0.0003387157,0.00002715501,0.002195768],"genre_scores_gemma":[0.9977117,0.0004871961,0.0001042891,0.0001565905,0.00005826891,0.0000265863,0.0006945359,0.000007834873,0.0007530715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001298954,"threshold_uncertainty_score":0.004082739,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0274594783006836,"score_gpt":0.3419865786908813,"score_spread":0.3145271003901977,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}